CA3245423A1 - COMPOSITIONS AND METHODS COMPRISING A MODIFIED SMALL NUCLEAR RNA (SNRNA) - Google Patents
COMPOSITIONS AND METHODS COMPRISING A MODIFIED SMALL NUCLEAR RNA (SNRNA)Info
- Publication number
- CA3245423A1 CA3245423A1 CA3245423A CA3245423A CA3245423A1 CA 3245423 A1 CA3245423 A1 CA 3245423A1 CA 3245423 A CA3245423 A CA 3245423A CA 3245423 A CA3245423 A CA 3245423A CA 3245423 A1 CA3245423 A1 CA 3245423A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- sequence
- targeting
- esnrna
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263316659P | 2022-03-04 | 2022-03-04 | |
| US63/316,659 | 2022-03-04 | ||
| US202263379983P | 2022-10-18 | 2022-10-18 | |
| US63/379,983 | 2022-10-18 | ||
| PCT/US2023/063798 WO2023168458A1 (en) | 2022-03-04 | 2023-03-06 | Compositions and methods comprising engineered small nuclear rna (snrna) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3245423A1 true CA3245423A1 (en) | 2023-09-07 |
Family
ID=85792399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3245423A Pending CA3245423A1 (en) | 2022-03-04 | 2023-03-06 | COMPOSITIONS AND METHODS COMPRISING A MODIFIED SMALL NUCLEAR RNA (SNRNA) |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20230279397A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4486888A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025507958A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240164824A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119137273A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023228712A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245423A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315378A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010833A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023168458A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230279397A1 (en) | 2022-03-04 | 2023-09-07 | Locanabio, Inc. | Compositions and methods comprising engineered short nuclear rna (snrna) |
| EP4605529A1 (en) | 2022-10-18 | 2025-08-27 | Regeneron Pharmaceuticals, Inc. | Compositions and methods comprising programmable snrnas for rna editing |
| CN120548368A (zh) | 2022-12-01 | 2025-08-26 | 再生元制药公司 | 用于正确包装重复元件的腺相关病毒载体 |
| EP4784751A2 (en) | 2023-09-26 | 2026-08-05 | Regeneron Pharmaceuticals, Inc. | Compositions and methods comprising small nuclear rna (snrna) for treating dmd |
| WO2025090628A1 (en) | 2023-10-23 | 2025-05-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods comprising small nuclear rna (snrna) for treating genetic epilepsies |
| IL328914A (en) | 2023-12-15 | 2026-08-01 | Regeneron Pharmaceuticals Inc | Compositions and methods comprising small nuclear RNA (snRNA) targeting SOD1 |
| WO2025160364A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Compositions and methods comprising small nuclear rna (snrna) for the treatment of pompe disease |
| WO2026090560A1 (en) * | 2024-10-25 | 2026-04-30 | Crank Bio, Inc. | Engineered nucleic acids and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1283876B1 (it) | 1996-01-12 | 1998-05-07 | Univ Roma | Molecole chimeriche ribozima-snrna ad attivita' catalitica per rna a localizzazione nucleare |
| US5814500A (en) | 1996-10-31 | 1998-09-29 | The Johns Hopkins University School Of Medicine | Delivery construct for antisense nucleic acids and methods of use |
| US6692910B2 (en) | 1997-07-28 | 2004-02-17 | The University Of Connecticut | Inhibition of a target messenger RNA with a modified U1 small nuclear RNA |
| JP2004514407A (ja) | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター |
| EP1384784A1 (en) | 2001-03-30 | 2004-01-28 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Method for reversible inhibition of gene expression by modified ribonucleoproteins |
| ITRM20020253A1 (it) | 2002-05-08 | 2003-11-10 | Univ Roma | Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche. |
| FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
| US8822168B2 (en) | 2005-03-11 | 2014-09-02 | The Trustees Of The University Of Pennsylvania | Assays for detecting small nuclear ribonucleoprotein particle assembly and survival of motor neurons activity |
| US9040491B2 (en) | 2006-08-30 | 2015-05-26 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits based on small nuclear RNAs |
| US9441221B2 (en) | 2007-03-30 | 2016-09-13 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
| EP2142672B1 (en) | 2007-03-30 | 2012-09-05 | Rutgers, The State University of New Jersey | Compositions and methods for gene silencing |
| US8343941B2 (en) | 2007-03-30 | 2013-01-01 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
| US8907075B2 (en) | 2007-03-30 | 2014-12-09 | Samuel Ian Gunderson | Compositions and methods for gene silencing |
| DK2623605T3 (en) | 2007-04-09 | 2019-03-25 | Univ Florida | RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF |
| ES2566553T3 (es) * | 2010-03-17 | 2016-04-13 | Association Institut De Myologie | ARNnp U7 modificados para el tratamiento de las enfermedades neuromusculares |
| IT1400425B1 (it) | 2010-06-08 | 2013-05-31 | Amsterdam Molecular Therapeutics Bv | Modified snrnas for use in therapy. |
| IT1405793B1 (it) | 2010-10-15 | 2014-01-24 | Univ Ferrara | Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica |
| US9303258B2 (en) | 2011-04-05 | 2016-04-05 | The Regents Of The University Of California | Method and compositions comprising small RNA agonist and antagonists to modulate inflammation |
| US9862945B2 (en) | 2013-04-20 | 2018-01-09 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs |
| CA2957661A1 (en) | 2014-08-09 | 2016-02-18 | Kevin FLANIGAN | Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene |
| US9669109B1 (en) | 2015-11-24 | 2017-06-06 | Universita Di Ferrara | Modified human U1snRNA molecule, a gene encoding for the modified human U1snRNA molecule, an expression vector including the gene, and the use thereof in gene therapy of familial dysautonomia and spinal muscular atrophy |
| FR3044926B1 (fr) | 2015-12-09 | 2020-01-31 | Genethon | Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine |
| JP6966463B2 (ja) | 2016-02-26 | 2021-11-17 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 組換えウイルス産物及びdux4エクソンスキッピングを誘導するための方法 |
| AU2019326551A1 (en) | 2018-08-22 | 2021-03-18 | Research Institute At Nationwide Children's Hospital | Recombinant virus products and methods for inhibiting expression of dystrophia myotonica protein kinase and/or interfering with a trinucleotide repeat expansion in the 3' untranslated region of the DMPK gene |
| JP2022524383A (ja) | 2019-03-08 | 2022-05-02 | ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー | ハンチントン病を処置するための組成物および方法 |
| JP2022520885A (ja) | 2019-03-26 | 2022-04-01 | ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー | 神経変性疾患を処置するための組成物および方法 |
| WO2020214763A1 (en) * | 2019-04-18 | 2020-10-22 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| EP4004204A1 (en) | 2019-07-23 | 2022-06-01 | Oxford BioMedica (UK) Limited | Enhancing production of lentiviral vectors |
| US20220282247A1 (en) | 2019-08-02 | 2022-09-08 | Research Institute At Nationwide Children's Hospital | Exon 44-targeted nucleic acids and recombinant adeno-associated virus comprising said nucleic acids for treatment of dystrophin-based myopathies |
| IL293671A (en) | 2019-12-09 | 2022-08-01 | Astellas Pharma Inc | Antisense guide RNA with an additional functional region for target RNA editing |
| CA3173012A1 (en) * | 2020-04-22 | 2021-10-28 | Susan BYRNE | Compositions and methods using snrna components |
| US20240261434A1 (en) | 2020-09-28 | 2024-08-08 | Research Institute At Nationwide Children's Hospital | Products and methods for treating muscular dystrophy |
| CA3203585A1 (en) | 2020-11-30 | 2022-06-02 | Research Institute At Nationwide Children's Hospital | Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd) |
| AU2022262420A1 (en) | 2021-04-23 | 2023-11-16 | Research Institute At Nationwide Children's Hospital | Products and methods for treating muscular dystrophy |
| US20230279397A1 (en) | 2022-03-04 | 2023-09-07 | Locanabio, Inc. | Compositions and methods comprising engineered short nuclear rna (snrna) |
-
2023
- 2023-03-06 US US18/179,110 patent/US20230279397A1/en active Pending
- 2023-03-06 IL IL315378A patent/IL315378A/en unknown
- 2023-03-06 KR KR1020247032973A patent/KR20240164824A/ko active Pending
- 2023-03-06 CA CA3245423A patent/CA3245423A1/en active Pending
- 2023-03-06 WO PCT/US2023/063798 patent/WO2023168458A1/en not_active Ceased
- 2023-03-06 AU AU2023228712A patent/AU2023228712A1/en active Pending
- 2023-03-06 EP EP23714451.4A patent/EP4486888A1/en active Pending
- 2023-03-06 CN CN202380037529.8A patent/CN119137273A/zh active Pending
- 2023-03-06 JP JP2024552401A patent/JP2025507958A/ja active Pending
- 2023-08-10 US US18/447,651 patent/US12037588B2/en active Active
-
2024
- 2024-06-04 US US18/733,477 patent/US20250136981A1/en active Pending
- 2024-09-04 MX MX2024010833A patent/MX2024010833A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230279397A1 (en) | 2023-09-07 |
| KR20240164824A (ko) | 2024-11-20 |
| IL315378A (en) | 2024-11-01 |
| AU2023228712A1 (en) | 2024-10-17 |
| CN119137273A (zh) | 2024-12-13 |
| EP4486888A1 (en) | 2025-01-08 |
| WO2023168458A1 (en) | 2023-09-07 |
| JP2025507958A (ja) | 2025-03-21 |
| US20250136981A1 (en) | 2025-05-01 |
| US12037588B2 (en) | 2024-07-16 |
| US20240018521A1 (en) | 2024-01-18 |
| MX2024010833A (es) | 2024-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12037588B2 (en) | Compositions and methods comprising engineered short nuclear RNA (snRNA) | |
| WO2023154807A2 (en) | Compositions and methods for modulating pre-mrna splicing | |
| US20240108751A1 (en) | Rna-targeting compositions and methods for treating myotonic dystrophy type 1 | |
| US20240000972A1 (en) | Rna-targeting compositions and methods for treating cag repeat diseases | |
| CN113557243A (zh) | 用于神经变性疾病的基因疗法 | |
| WO2024086650A1 (en) | Compositions and methods comprising programmable snrnas for rna editing | |
| EP4627093A1 (en) | Adeno-associated viral vectors for proper packaging of repetitive elements | |
| WO2023240162A1 (en) | Aav vectors for gene editing | |
| WO2023205637A1 (en) | Rna-targeting compositions and methods for treating c9/orf72 diseases | |
| AU2024350159A1 (en) | Compositions and methods comprising small nuclear rna (snrna) for treating dmd | |
| WO2022221278A1 (en) | Compositions and methods comprising hybrid promoters | |
| CN117320741A (zh) | 用于治疗cag重复疾病的靶向rna的组合物和方法 | |
| EA052057B1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ВКЛЮЧАЮЩИЕ СКОНСТРУИРОВАННУЮ МАЛУЮ ЯДЕРНУЮ РНК (snРНК) | |
| WO2025160364A2 (en) | Compositions and methods comprising small nuclear rna (snrna) for the treatment of pompe disease | |
| WO2025090633A1 (en) | Compositions and methods comprising small nuclear rna (snrna) for treating genetic epilepsies | |
| WO2025126158A2 (en) | Compositions and methods comprising small nuclear rna (snrna) targeting sod1 | |
| WO2025155722A1 (en) | Muscle selective hybrid regulatory combinations and methods of use thereof for the treatment of myotonic dystrophy type 1 | |
| CN116801901A (zh) | 用于治疗1型强直性肌营养不良的靶向rna的组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240903 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240904 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240904 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240904 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250221 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250411 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250416 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251204 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260219 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260728 |